Cutaneous drug eruptions associated with the use of new oncological drugs

Chemical Immunology and Allergy

Volumn 97, Issue , 2012, Pages 191-202

  Belloni, Benedetta ^a   Schönewolf, Nicola ^a   Rozati, Sima ^a   Goldinger, Simone M ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CETUXIMAB; DACARBAZINE; DISINFECTANT AGENT; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; PANITUMUMAB; PETROLATUM; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID; SALICYLIC ACID; SELUMETINIB; SORAFENIB; STEROID; SUNITINIB; TETRACYCLINE; UREA; VEMURAFENIB;

ACTINIC KERATOSIS; ALOPECIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ARTICLE; BLURRED VISION; BREAST CANCER; CHEILITIS; COLON CANCER; DEBRIDEMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TARGETING; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EYE DISEASE; FACE ERYTHEMA; FATIGUE; FOLLICULITIS; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; HAIR DEPIGMENTATION; HAIR DISEASE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; HYPOMAGNESEMIA; INFUSION RELATED REACTION; KERATOACANTHOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MACULOPAPULAR RASH; MELANOMA; NAUSEA; PAINLESS SUBUNGUAL SPLINTER HEMORRHAGE; PALMOPLANTAR DYSESTHESIA; PAPULOPUSTULAR RASH; PARONYCHIA; PHOTOSENSITIVITY; PODIATRY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RADIATION DERMATITIS; SCALP DYSESTHESIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SUBUNGUAL SPLINTER HEMORRHAGE; TELANGIECTASIA; TREATMENT DURATION; TRICHOMEGALY; TRICHORRHEXIS; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; ERYTHEMA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; HYPERPIGMENTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIODERMATITIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861447222     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000335632     Document Type: Article

References (27)

1. Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002;14:212-216.
2. Remlinger KA: Cutaneous reactions to chemotherapy drugs: the art of consultation. Arch Dermatol 2003;139:77-81.
3. Sun QM, Miao ZH, Lin LP, Gui M, Zhu CH, Xie H, Duan WH, Ding J: BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities. Cancer Biol Ther 2009;8:1640-1647.
4. Reck M, Gutzmer R: Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 2010;33:470-479.
5. Hammond-Thelin LA: Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008;26:121-159, ix.
6. Fakih M, Vincent M: Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17(suppl 1): S18-S30.
7. Gerber PA, Buhren BA, Kurle S, Homey B: Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects (in German). Hautarzt 2010;61:654-661.
8. Fox LP: Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007;56:460-465.
9. Gerber PA, Homey B: Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 2008;358:1175.
10. Giro C, Berger B, Bolke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, Langendijk JA, Budach W: High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009;90:166-171.
11. Wilhelm SM, Carter C, Tang L, Wilkie D, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64: 7099-7109.
12. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM: SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002;16: 681-690.
13. Arora A, Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-979.
14. Autier J, Escudier B, Wechsler J, Spatz A, Robert C: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-892.
15. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B: Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305.
16. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK: Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161:1045-1051.
17. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW: Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-596.
18. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME: Search for evidence-based approaches for the prevention and palliation of handfoot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009;14:291-302.
19. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP: Evolving strategies for the management of handfoot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-1011.
20. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T: Cutaneous sideeffects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
21. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B: Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42:548-556.
22. Bollag G, Hirth P, Tsai J, Zhang J, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467: 596-599.
23. Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J, O'Dwyer P, Lee R, Grippo J, Nolop K, Chapman P: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363: 809-819.
24. Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J, McArthur G, Hutson T, Lawrence D, Moschos S, Flaherty K, Hersey P, Kefford R, Chmielowski B, Amaravadi R, Puzanov I, Li J, Bhattacharya S, Nolop K, Lee R, Joe A, Ribas A: An open-label, multicenter Phase II study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutationpositive metastatic melanoma. Oral abstract, Society for Melanoma Research meeting 2010. Pigment Cell Melanoma Res 2010;23:912.
25. Cichowski K, Jänne P: Drug discovery: inhibitors that activate. Nature 2010;464:358-359.
26. Schad K, Baumann Conzett K, Zipser M, Enderlin V, Kamarashev J, French L, Dummer R: Mitogenactivated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010;16:1058-1064.
27. Adjei A, Cohen R, Franklin W, Morris C, Wilson D, Molina J, Hanson L, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt S: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-2146.